MLICM
ALXO icon

Metropolitan Life Insurance Company (MetLife)’s ALX Oncology ALXO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,579
Closed -$17.6K – 109
2024
Q1 		$17.6K Hold
1,579
– – ﹤0.01% 1926
2023
Q4 		$23.5K Buy
+1,579
New +$15K ﹤0.01% 1846
2023
Q3 		– Sell
-1,201
Closed -$9.02K – 2402
2023
Q2 		$9.02K Buy
+1,201
New +$7.86K ﹤0.01% 2346
2023
Q1 		– Sell
-1,308
Closed -$14.7K – 2314
2022
Q4 		$14.7K Hold
1,308
– – ﹤0.01% 2136
2022
Q3 		$12.5K Buy
+1,308
New +$15.2K ﹤0.01% 2234
2022
Q2 		– Sell
-1,242
Closed -$21K – 2371
2022
Q1 		$21K Sell
1,242
-3,965
-76% -$67.7K ﹤0.01% 2071
2021
Q4 		$112K Hold
5,207
– – ﹤0.01% 2412
2021
Q3 		$385K Buy
+5,207
New +$347K 0.01% 1621
2021
Q2 		– Sell
-4,954
Closed -$365K – 2716
2021
Q1 		$365K Buy
4,954
+1,953
+65% +$154K 0.01% 1611
2020
Q4 		$259K Hold
3,001
– – ﹤0.01% 1765
2020
Q3 		$113K Buy
+3,001
New +$118K ﹤0.01% 2147

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ALXO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 1,579 shares — an estimated $17.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ALXO in Q3 2020 and held it in 11 quarters. The position peaked at $385K in Q3 2021. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,579 ALX Oncology shares in Q2 2024, an estimated $17.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in ALX Oncology in Q3 2020 and held it in 11 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s ALX Oncology position peaked at $385K in Q3 2021.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.